PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform...

Full description

Bibliographic Details
Main Authors: Ben Fulton, Susan C. Short, Allan James, Stefan Nowicki, Catherine McBain, Sarah Jefferies, Caroline Kelly, Jon Stobo, Anna Morris, Aoife Williamson, Anthony J. Chalmers
Format: Article
Language:English
Published: Elsevier 2018-01-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Glioblastoma
Poly(ADP-ribose) polymerase
Olaparib
Radiotherapy
O6-methylguanine methyltransferase
Dose escalation
Radiosensitizer
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630817300885
id doaj-69f6ccf5e2064209ba6e1bb4069d7193
record_format Article
spelling doaj-69f6ccf5e2064209ba6e1bb4069d71932021-06-02T03:39:55ZengElsevierClinical and Translational Radiation Oncology2405-63082018-01-018C121610.1016/j.ctro.2017.11.003PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT statusBen Fulton0Susan C. Short1Allan James2Stefan Nowicki3Catherine McBain4Sarah Jefferies5Caroline Kelly6Jon Stobo7Anna Morris8Aoife Williamson9Anthony J. Chalmers10Institute of Cancer Sciences, University of Glasgow, UKLeeds Institute of Cancer and Pathology, University of Leeds, UKBeatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UKBeatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UKChristie NHS Foundation Trust, Manchester, UKAddenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKInstitute of Cancer Sciences, University of Glasgow, UKInstitute of Cancer Sciences, University of Glasgow, UKInstitute of Cancer Sciences, University of Glasgow, UKBeatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UKInstitute of Cancer Sciences, University of Glasgow, UKGlioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.http://www.sciencedirect.com/science/article/pii/S2405630817300885GlioblastomaPoly(ADP-ribose) polymeraseOlaparibRadiotherapyO6-methylguanine methyltransferaseDose escalationRadiosensitizer
collection DOAJ
language English
format Article
sources DOAJ
author Ben Fulton
Susan C. Short
Allan James
Stefan Nowicki
Catherine McBain
Sarah Jefferies
Caroline Kelly
Jon Stobo
Anna Morris
Aoife Williamson
Anthony J. Chalmers
spellingShingle Ben Fulton
Susan C. Short
Allan James
Stefan Nowicki
Catherine McBain
Sarah Jefferies
Caroline Kelly
Jon Stobo
Anna Morris
Aoife Williamson
Anthony J. Chalmers
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
Clinical and Translational Radiation Oncology
Glioblastoma
Poly(ADP-ribose) polymerase
Olaparib
Radiotherapy
O6-methylguanine methyltransferase
Dose escalation
Radiosensitizer
author_facet Ben Fulton
Susan C. Short
Allan James
Stefan Nowicki
Catherine McBain
Sarah Jefferies
Caroline Kelly
Jon Stobo
Anna Morris
Aoife Williamson
Anthony J. Chalmers
author_sort Ben Fulton
title PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_short PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_full PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_fullStr PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_full_unstemmed PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
title_sort paradigm-2: two parallel phase i studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by mgmt status
publisher Elsevier
series Clinical and Translational Radiation Oncology
issn 2405-6308
publishDate 2018-01-01
description Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.
topic Glioblastoma
Poly(ADP-ribose) polymerase
Olaparib
Radiotherapy
O6-methylguanine methyltransferase
Dose escalation
Radiosensitizer
url http://www.sciencedirect.com/science/article/pii/S2405630817300885
work_keys_str_mv AT benfulton paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT susancshort paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT allanjames paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT stefannowicki paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT catherinemcbain paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT sarahjefferies paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT carolinekelly paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT jonstobo paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT annamorris paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT aoifewilliamson paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
AT anthonyjchalmers paradigm2twoparallelphaseistudiesofolaparibandradiotherapyorolaparibandradiotherapyplustemozolomideinpatientswithnewlydiagnosedglioblastomawithtreatmentstratifiedbymgmtstatus
_version_ 1721408729993183232

Similar Items